InPsytech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	601.07	404.18	290.36
Revenue Growth	48.71%	39.20%	-
Gross Profit	601.07	404.18	290.36
Selling, General & Admin	108.49	38.06	79.66
Research & Development	323.81	138.94	244.99
Operating Expenses	436.28	177	324.65
Operating Income	164.79	227.19	-34.29
Interest Expense	-0	-0.13	-0.09
Interest & Investment Income	14.94	26.66	14.55
Currency Exchange Gain (Loss)	-10.82	31.28	-3.41
Other Non Operating Income (Expenses)	25.95	11.97	12.68
Pretax Income	194.86	296.96	-10.56
Income Tax Expense	32.82	59.37	-3.04
Net Income	162.04	237.59	-7.52
Net Income to Common	162.04	237.59	-7.52
Net Income Growth	-31.80%	-	-
Shares Outstanding (Basic)	29	13	14
Shares Outstanding (Diluted)	29	13	14
Shares Change	129.44%	-6.34%	-
EPS (Basic)	5.60	18.81	-0.56
EPS (Diluted)	5.58	18.78	-0.56
EPS Growth	-70.29%	-	-

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-2.5	262.7	218.42
Free Cash Flow Per Share	-0.09	20.77	16.18
Dividend Per Share	1.000	45.000	6.630
Dividend Growth	-97.78%	578.73%	-
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	27.42%	56.21%	-11.81%
Profit Margin	26.96%	58.78%	-2.59%
Free Cash Flow Margin	-0.42%	65.00%	75.22%
EBITDA	169.35	231.22	-32.34
EBITDA Margin	28.18%	57.21%	-11.14%
D&A For EBITDA	4.56	4.03	1.95
EBIT	164.79	227.19	-34.29
EBIT Margin	27.42%	56.21%	-11.81%
Effective Tax Rate	16.84%	19.99%	-